Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Greg22 who wrote (22513)	9/26/1999 12:52:00 AM
From: Patscara	Read Replies (1) \| Respond to of 23519

>>Now, what's wrong with this picture?<< Lee Wilson, US marketing partner & someone who knows how to market/sell what this company has to offer. Albria will defiantly bring much needed help to Vivus, but we still have the above three problems.

To: Greg22 who wrote (22513)	9/26/1999 9:43:00 AM
From: Frostman	Read Replies (1) \| Respond to of 23519

Not sure, but this element may be in contention: 2.) Higher efficacy rate v. Viagra Who has current numbers on Viagra efficacy? I recall some big numbers posted recently in some difficult categories like prostate patients. I think "overall" has crept up as well. Can someone roll out recent Viagra and Alibra stats? Yes!, some very good sales points that Viagra can't touch. * safety profile * on demand results (hopefully, with more difficult etiology... and smaller placebo effect) * local VS systemic Interesting discussion in the last few posts on RB as to partnership problems and potential, Alibra Launch, and future of Muse after ALibra: millstone or marketable? Frostman